15 citations
,
March 2007 in “Hormones and Behavior” Finasteride boosts morphine's pain relief, stops tolerance, and reduces withdrawal in rats.
February 2023 in “Reactions Weekly”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
20 citations
,
August 2019 in “Expert Opinion on Drug Safety” Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.
37 citations
,
January 1986 in “Carcinogenesis” ODC expression in mouse skin and tumors is varied and can be inhibited by retinoic acid or cycloheximide.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
July 2023 in “Developmental medicine and child neurology/Developmental medicine & child neurology” DFMO treatment improves hair growth, muscle tone, and development in Bachmann-Bupp syndrome patients.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
22 citations
,
February 2008 in “Journal of Neurochemistry” Minoxidil prevents serotonin loss from MDMA by affecting potassium channels and increasing Akt phosphorylation.
14 citations
,
January 2022 in “Evidence-based Complementary and Alternative Medicine” Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
17 citations
,
July 2013 in “Amino Acids” Increased ODC activity leads to skin tumors by recruiting stem cells, not by toxic byproducts.
3 citations
,
August 2014 in “Steroids” Fermentation of Finasteride with Ocimum sanctum L. creates new metabolite that inhibits tyrosinase.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
8 citations
,
August 2015 in “European Journal of Clinical Pharmacology” Rivaroxaban may cause hair loss.
133 citations
,
November 2018 in “Aging” Azithromycin and Roxithromycin can remove aging cells and may help with anti-aging.
6 citations
,
August 2004 in “Journal of Chemical Information and Computer Sciences” The research found a link between certain molecular features and the biological activity of BC3, which can help identify or create new active compounds.
25 citations
,
October 2018 in “Journal of Mind and Medical Sciences” New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
13 citations
,
January 1987 in “Dermatology” Minoxidil sulfate relaxes blood vessels by increasing potassium permeability.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
September 1999 in “Molecular Carcinogenesis” Increased ODC expression makes normally tumor-resistant mice more prone to tumor development.
8 citations
,
October 2013 in “Chemistry Central Journal” Metabolite 7 is a strong inhibitor for Alzheimer's disease management.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.